Related Experiment Video
Updated: Nov 19, 2025

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
Published on: September 13, 2019
MYBPC2 and MYL1 as Significant Gene Markers for Rhabdomyosarcoma
Zihang Chen1, Xing-Yu Li2, Peng Guo3
1General Surgery Department, Hangzhou Fuyang District First People's Hospital, Hangzhou, People's Republic of China.
Insights
This study identified differentially expressed genes in pediatric rhabdomyosarcoma, finding that high expression of MYBPC2 and MYL1 correlates with poorer survival. These genes may be key targets for rhabdomyosarcoma treatment.
Area of Science:
- Oncology
- Molecular Biology
- Pediatric Cancer Research
Background:
- Rhabdomyosarcoma is the most common pediatric soft tissue tumor.
- It frequently causes pain, bleeding, metastasis, and recurrence, impacting prognosis.
- Understanding its molecular mechanisms is crucial for effective treatment.
Purpose of the Study:
- To identify molecular mechanisms and potential therapeutic targets in rhabdomyosarcoma.
- To explore differentially expressed genes between tumor and healthy tissues.
- To investigate the prognostic significance of identified genes.
Main Methods:
- Utilized GEO2R to analyze gene expression data from rhabdomyosarcoma and healthy samples.
- Performed pathway enrichment analysis (KEGG, GO) and constructed a protein-protein interaction network.
- Validated hub gene expression (MYBPC2, MYL1) using RT-qPCR and assessed survival using Kaplan-Meier analysis.
Main Results:
- Identified 164 upregulated and 394 downregulated genes in rhabdomyosarcoma.
- Enrichment analysis highlighted cell cycle, muscle contraction, and cytoskeleton pathways.
- MYBPC2 and MYL1 were significantly upregulated hub genes associated with worse overall survival.
Conclusions:
- Differentially expressed genes, particularly MYBPC2 and MYL1, were identified in rhabdomyosarcoma.
- These genes may play a role in rhabdomyosarcoma pathogenesis.
- MYBPC2 and MYL1 warrant further investigation as potential diagnostic and therapeutic targets.
Background:
Rhabdomyosarcoma is the most common soft tissue tumor in children. Rhabdomyosarcoma commonly results in pain and bleeding caused by tumor compression and is prone to early metastasis and recurrence, which can seriously affect the therapeutic outcomes and long-term prognosis. Up to 37.7% of rhabdomyosarcomas may metastasize. Therefore, the molecular mechanisms underlying rhabdomyosarcoma must be explored to identify an effective target for its early diagnosis and specific treatment.
Methods:
A dataset of 18 rhabdomyosarcoma tissue samples and 6 healthy skeletal muscle samples was downloaded. Differentially expressed genes between rhabdomyosarcoma and healthy tissue samples were identified by GEO2R. Kyoto Encyclopedia of Genes and Genomes and gene ontology pathway enrichment analyses were performed. A protein-protein interaction network was constructed, and hub genes were identified. Expression and survival analyses of hub genes were performed. Additionally, 30 patients with rhabdomyosarcoma were recruited, and overall survival information and samples were collected. Reverse transcription quantitative real-time polymerase chain reaction assays were performed to verify the expression of MYBPC2 and MYL1 in rhabdomyosarcoma tumor tissues. The Kaplan-Meier method was used to explore overall survival based on our clinical data.
Results:
In total, 164 genes were up-regulated and 394 were down-regulated in rhabdomyosarcoma tumor tissues. Gene ontology analysis revealed that variations were predominantly enriched in the cell cycle, muscle contraction, muscle system processes, cytoskeleton, nucleotide binding, and cytoskeletal protein binding. The protein-protein interaction network revealed 3274 edges, and 441 nodes were constructed. Ten hub genes were identified; of these, MYBPC2 and MYL1 were significantly up-regulated in rhabdomyosarcoma. Compared with the healthy group, patients with rhabdomyosarcoma exhibiting high expression of MYBPC2 and MYL1 exhibited significantly worse overall survival.
Conclusions:
We found differentially expressed genes between rhabdomyosarcoma and healthy tissue samples. MYBPC2 and MYL1 may be involved in the pathogenesis of rhabdomyosarcoma and therefore deserve further exploration.
More Related Videos
08:57Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
Published on: May 17, 2024
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
Related Concept Videos
Abnormal Proliferation
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
The Ras Gene
Ras is a...
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...